Correlates of Vaccine-Induced Protection against SARS-CoV-2.
Till Koch,Sibylle C. Mellinghoff,Parichehr Shamsrizi,Parichehr Shamsrizi,Marylyn M. Addo,Marylyn M. Addo,Christine Dahlke,Christine Dahlke +7 more
TLDR
In this paper, the authors report on immunogenicity against natural SARS-CoV-2 infection, vaccine-induced immune responses and discuss immunological markers that can be linked to protection.About:
This article is published in Vaccine.The article was published on 2021-03-10 and is currently open access. It has received 44 citations till now. The article focuses on the topics: Vaccine efficacy & Vaccination.read more
Citations
More filters
Journal ArticleDOI
Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19.
Brian J. Ward,Philipe Gobeil,Annie Séguin,Judith Atkins,Iohann Boulay,Pierre-Yves Charbonneau,Manon Couture,Marc-André D'Aoust,Jiwanjeet Dhaliwall,Carolyn Finkle,Karen Hager,Asif Mahmood,Alexander I. Makarkov,Matthew P. Cheng,Stéphane Pillet,Patricia Schimke,Sylvie St-Martin,Sonia Trépanier,Nathalie Landry +18 more
TL;DR: In this paper, the authors report Day 42 interim safety and immunogenicity data from an observer-blinded, dose escalation, randomized controlled study of a virus-like particle vaccine candidate produced in plants that displays the SARS-CoV-2 spike glycoprotein (CoVLP: NCT04450004 ).
Journal ArticleDOI
Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern.
Donal T. Skelly,Adam Harding,Javier Gilbert-Jaramillo,Michael L. Knight,S Longet,S Longet,Anthony Brown,S Adele,Emily Adland,Harriet R. Brown,T Tipton,T Tipton,L Stafford,Alexander J. Mentzer,S A Johnson,Ali Amini,Tiong Kit Tan,Lisa Schimanski,Huang K-Ya.,Pramila Rijal,Cmore,John Frater,P Goulder,Christopher P. Conlon,Katie Jeffery,Christina Dold,Andrew J. Pollard,Alex Sigal,Alex Sigal,T de Oliveira,T de Oliveira,Alain Townsend,Paul Klenerman,Susanna Dunachie,E Barnes,Miles W. Carroll,Miles W. Carroll,William James +37 more
TL;DR: In this article, the extent to which immune responses to natural infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and immunization with vaccines protect against variants of concern (VOC) is investigated.
Journal ArticleDOI
Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?
Gregory Milne,Gregory Milne,Thomas J. Hames,Chris J. Scotton,Nick Gent,Alexander Johnsen,Roy M. Anderson,Thomas Ward +7 more
TL;DR: In this article, the authors show that SARS-CoV-2 infection elicits an adaptive immune response against a large breadth of viral epitopes, although the duration of the response varies with age and disease severity.
Journal ArticleDOI
T helper type (Th1/Th2) responses to SARS-CoV-2 and influenza A (H1N1) virus: From cytokines produced to immune responses.
Elahe Aleebrahim-Dehkordi,Ali Hasanpour Dehkordi,Bahareh Molavi,Melika Mokhtari,Niloofar Deravi,Mobina Fathi,Tara Fazel,Mehdi Mohebalizadeh,Pooneh Koochaki,Parnian Shobeiri,Ali Hasanpour-Dehkordi +10 more
TL;DR: In this article, the authors compared the Th1 and Th2 cells responses in SARS-CoV-2 and H1N1 and found that insufficient levels and high levels of specific cytokines can have side effects.
References
More filters
Journal ArticleDOI
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Fernando P. Polack,Stephen J. Thomas,Nicholas Kitchin,Judith Absalon,Alejandra Gurtman,Stephen Lockhart,John L. Perez,Gonzalo Pérez Marc,Edson D. Moreira,Cristiano Zerbini,Ruth Bailey,Kena A. Swanson,Satrajit Roychoudhury,Kenneth Koury,Ping Li,Warren Kalina,David A. Cooper,Robert W. Frenck,Laura L. Hammitt,Özlem Türeci,Haylene Nell,Axel Schaefer,Serhat Ünal,Dina B. Tresnan,Susan Mather,Philip R. Dormitzer,Ugur Sahin,Kathrin U. Jansen,William C. Gruber +28 more
TL;DR: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older and safety over a median of 2 months was similar to that of other viral vaccines.
Journal ArticleDOI
Pathological findings of COVID-19 associated with acute respiratory distress syndrome.
Zhe Xu,Lei Shi,Yijin Wang,Ji-Yuan Zhang,Lei Huang,Chao Zhang,Shuhong Liu,Peng Zhao,Hongxia Liu,Li Zhu,Yanhong Tai,Changqing Bai,Tingting Gao,Jin-Wen Song,Peng Xia,Jing-Hui Dong,Jingmin Zhao,Fu-Sheng Wang +17 more
TL;DR: O surto do novo coronavÃrus (COVID-19) em Wuhan, China, iniciado em dezembro de 2019, evoluiu para se tornar uma pandemia global A.
Journal ArticleDOI
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
Merryn Voysey,Clemens Sac.,Shabir A. Madhi,Lily Yin Weckx,P M Folegatti,Parvinder K. Aley,Brian Angus,Vicky L. Baillie,Shaun Barnabas,Q E Bhorat,S Bibi,Carmen Briner,P Cicconi,Andrea M. Collins,R Colin-Jones,Clare L. Cutland,Thomas C. Darton,Keertan Dheda,Duncan Cja.,Emary Krw.,Katie J. Ewer,Lee Fairlie,Saul N. Faust,Shuo Feng,Daniela M. Ferreira,Adam Finn,Anna Goodman,Catherine M. Green,Christopher A Green,Paul T. Heath,Christopher Hill,Helen Hill,Ian Hirsch,Hodgson Shc.,Allen Izu,S Jackson,D Jenkin,Joe Ccd.,S Kerridge,Anthonet Koen,Gaurav Kwatra,Rajeka Lazarus,Alison M. Lawrie,A Lelliott,Vincenzo Libri,Patrick J. Lillie,R Mallory,Mendes Ava.,Eveline Pipolo Milan,Angela M. Minassian,Alastair McGregor,Hazel Morrison,Y Mujadidi,Amit J Nana,P J O’Reilly,S D Padayachee,A Pittella,E Plested,Katrina M Pollock,M N Ramasamy,S Rhead,Alexandre Vargas Schwarzbold,Nisha Singh,Andrew Smith,R Song,Matthew D. Snape,Eduardo Sprinz,Rebecca K. Sutherland,R Tarrant,E. Thomson,M E Török,Mark Toshner,Turner Dpj.,Johan Vekemans,Tonya Villafana,Watson Mee.,C J Williams,Alexander D. Douglas,Hill Avs.,Teresa Lambe,Sarah C. Gilbert,Andrew J. Pollard +81 more
TL;DR: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials.
Journal ArticleDOI
Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals.
Alba Grifoni,Daniela Weiskopf,Sydney I. Ramirez,Sydney I. Ramirez,Jose Mateus,Jennifer M. Dan,Jennifer M. Dan,Carolyn Rydyznski Moderbacher,Stephen A. Rawlings,Aaron Sutherland,Lakshmanane Premkumar,Ramesh Jadi,Daniel Marrama,Aravinda M. de Silva,April Frazier,Aaron F. Carlin,Jason A. Greenbaum,Bjoern Peters,Bjoern Peters,Florian Krammer,Davey M. Smith,Shane Crotty,Shane Crotty,Alessandro Sette,Alessandro Sette +24 more
TL;DR: Using HLA class I and II predicted peptide ‘megapools’, circulating SARS-CoV-2−specific CD8+ and CD4+ T cells were identified in ∼70% and 100% of COVID-19 convalescent patients, respectively, suggesting cross-reactive T cell recognition between circulating ‘common cold’ coronaviruses and SARS.
Journal ArticleDOI
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
Lindsey R. Baden,Hana M. El Sahly,Brandon Essink,Karen L. Kotloff,Sharon E. Frey,Rick Novak,David Diemert,Stephen A. Spector,Nadine Rouphael,C. Buddy Creech,John W McGettigan,Shishir Khetan,Nathan Segall,Joel Solis,Adam Brosz,Carlos Fierro,Howard J. Schwartz,Kathleen M. Neuzil,Lawrence Corey,Peter B. Gilbert,Holly Janes,Dean Follmann,Mary A. Marovich,John R. Mascola,Laura Polakowski,Julie E. Ledgerwood,Barney S. Graham,Hamilton Bennett,Rolando Pajon,Conor Knightly,Brett Leav,Weiping Deng,Honghong Zhou,Shu Liang Han,Melanie Ivarsson,Jacqueline Miller,Tal Z Zaks +36 more
TL;DR: The mRNA-1273 vaccine as discussed by the authors is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19.